|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shi T, Wang P, Xie C, Yin S, Shi D, Wei C,
Tang W, Jiang R, Cheng X, Wei Q, et al: BRCA1 and BRCA2 mutations
in ovarian cancer patients from China: Ethnic-related mutations in
BRCA1 associated with an increased risk of ovarian cancer. Int J
Cancer. 140:2051–2059. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eeles RA: Screening for hereditary cancer
and genetic testing, epitomized by breast cancer. Eur J Cancer.
35:1954–1962. 1999. View Article : Google Scholar
|
|
4
|
Miki Y, Swensen J, Shattuck-Eidens D,
Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM,
Ding W, et al: A strong candidate for the breast and ovarian cancer
susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chapman MS and Verma IM: Transcriptional
activation by BRCA1. Nature. 382:678–679. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kolinjivadi AM, Sannino V, de Antoni A,
Técher H, Baldi G and Costanzo V: Moonlighting at replication forks
- a new life for homologous recombination proteins BRCA1, BRCA2 and
RAD51. FEBS Lett. 591:1083–1100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J, Silver DP, Walpita D, Cantor SB,
Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM
and Scully R: Stable interaction between the products of the BRCA1
and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol
Cell. 2:317–328. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Narod SA, Brunet JS, Ghadirian P, Robson
M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B,
de los Rios P, et al: Tamoxifen and risk of contralateral breast
cancer in BRCA1 and BRCA2 mutation carriers: A case-control study.
Hereditary breast cancer clinical study group Lancet.
356:1876–1881. 2000.
|
|
9
|
Sakorafas GH and Tsiotou AG: Genetic
predisposition to breast cancer: A surgical perspective. Br J Surg.
87:149–162. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nicoletto MO, Donach M, De Nicolo A,
Artioli G, Banna G and Monfardini S: BRCA-1 and BRCA-2 mutations as
prognostic factors in clinical practice and genetic counselling.
Cancer Treat Rev. 27:295–304. 2001. View Article : Google Scholar
|
|
11
|
Cicero G, De Luca R, Dorangricchia P, Lo
Coco G, Guarnaccia C, Fanale D, Calò V and Russo A: Risk perception
and psychological distress in genetic counselling for hereditary
breast and/or ovarian cancer. J Genet Couns. 26:999–1007. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alvarez C, Aravena A, Tapia T, Rozenblum
E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A and
Carvallo P: Different Array CGH profiles within hereditary breast
cancer tumors associated to BRCA1 expression and overall survival.
Bmc Cancer. 16:2192016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ewald IP, Vargas FR, Moreira MA, Filho CM,
da Cunha DR, Ramos JP, Ribeiro PL, Caleffi M, Giuglani R and
Ashton-Prolla P: Prevalence of BRCA1 and BRCA2 founder mutations in
Brazilian hereditary breast and ovarian cancer families. J Clin
Oncol. 26:2008. View Article : Google Scholar
|
|
14
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:2013. View Article : Google Scholar
|
|
15
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao H, Langerød A, Ji Y, Nowels KW,
Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D,
Børresen-Dale AL and Jeffrey SS: Different gene expression patterns
in invasive lobular and ductal carcinomas of the breast. Mol Biol
Cell. 15:2523–2536. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Richardson AL, Wang ZC, De Nicolo A, Lu X,
Brown M, Miron A, Liao X, Iglehart JD, Livingston DM and Ganesan S:
X chromosomal abnormalities in basal-like human breast cancer.
Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mavaddat N, Peock S, Frost D, Ellis S,
Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, et al:
Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from
prospective analysis of EMBRACE. J Natl Cancer Inst. 105:812–822.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen S and Parmigiani G: Meta-analysis of
BRCA1 and BRCA2 penetrance. J Clin Oncol. 25:1329–1333. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blay P, Santamaria I, Pitiot AS, Luque M,
Alvarado MG, Lastra A, Fernández Y, Paredes A, Freije JM and Balbín
M: Mutational analysis of BRCA1 and BRCA2 in hereditary breast and
ovarian cancer families from Asturias (Northern Spain). BMC Cancer.
13:2432013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Petrucelli N, Daly MB and Feldman GL:
Hereditary breast and ovarian cancer due to mutations in BRCA1 and
BRCA2. Genet Mod. 12:245–259. 2010. View Article : Google Scholar
|
|
22
|
Taron M, Rosell R, Felip E, Mendez P,
Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ
and Maestre J: BRCA1 mRNA expression levels as an indicator of
chemoresistance in lung cancer. Hum Mol Genet. 13:2443–2449. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim MC, Choi JE, Lee SJ and Bae YK:
Coexistent loss of the expressions of BRCA1 and p53 predicts poor
prognosis in triple-negative breast cancer. Ann Surg Oncol.
23:3524–3530. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ju LL, Zhao CY, Ye KF, Yang H and Zhang J:
Expression and clinical implication of Beclin1, HMGB1, p62,
survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. Eur
Rev Med Pharmacol Sci. 20:1993–2003. 2016.PubMed/NCBI
|
|
26
|
Rajan JV, Wang M, Marquis ST and Chodosh
LA: Brca2 is coordinately regulated with Brca1 during proliferation
and differentiation in mammary epithelial cells. Proc Natl Acad Sci
USA. 93:13078–13083. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Welcsh PL and King MC: BRCA1 and BRCA2 and
the genetics of breast and ovarian cancer. Hum Mol Genet.
10:705–713. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Parvin S, Islam MS, Al-Mamun MM, Islam MS,
Ahmed MU, Kabir ER and Hasnat A: Association of BRCA1, BRCA2,
RAD51, and HER2 gene polymorphisms with the breast cancer risk in
the Bangladeshi population. Breast Cancer. 24:229–237. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Christou CM and Kyriacou K: BRCA1 and its
network of interacting partners. Biology. 2:40–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brems H, Beert E, de Ravel T and Legius E:
Mechanisms in the pathogenesis of malignant tumours in
neurofibromatosis type 1. Lancet Oncol. 10:508–515. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Campos B, Balmaña J, Gardenyes J,
Valenzuela I, Abad O, Fàbregas P, Volpini V and Díez O: Germline
mutations in NF1 and BRCA1 in a family with neurofibromatosis type
1 and early-onset breast cancer. Breast Cancer Res Treat.
139:597–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Madanikia SA, Bergner A, Ye X and Blakeley
JO: Increased risk of breast cancer in women with NF1. Am J Med
Genet A. 158A:3056–3060. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Masterson L, Sorgeloos F, Winder D,
Lechner M, Marker A, Malhotra S, Sudhoff H, Jani P, Goon P and
Sterling J: Deregulation of SYCP2 predicts early stage human
papillomavirus-positive oropharyngeal carcinoma: A prospective
whole transcriptome analysis. Cancer Sci. 106:1568–1575. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pannone G, Santoro A, Papagerakis S, Lo
Muzio L, De Rosa G and Bufo P: The role of human papillomavirus in
the pathogenesis of head & neck squamous cell carcinoma: An
overview. Infect Agent Cancer. 6:42011. View Article : Google Scholar
|
